Skip to main content

Table 5 Survival of patients with IIM at previous reports and this study

From: Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China

First author, published year (Ref)

location

Follow-up

Mean follow-up

No. of patients

Clinical-pathologic subgroup

Survival rates (%)

      

1-year

5-year

> 5-year

Medsger 1971 [10]

USA

1947-1968

7 years

124

PM, DM, JDM, OM, CAM

72

65

53(7 yr)

Benbassat1985 [8]

Israel

1956-1976

20 years

92

PM, DM, JDM, OM, CAM

72

52

--

Hochberg1986 [11]

USA

1970-1981

8 years

76

PM, DM, JDM, OM

94.5

80.4

72.8 (8 yr)

Maugars 1996 [9]

France

1973-1998

--

69

PM, DM, JDM, OM, CAM

82.6

66.7

55.4 (9 yr)

Uthman 1996[31]

France

1980-1992

5.2 years

30

PM, DM, CAM, OM

--

89

85(10 yr)

Marie 2001 [12]

France

1983-1999

4 years

77

PM, DM, CAM

83

77

61 (15 y)

Sultan 2002 [1]

England

1978-1999

20 years

46

PM, DM, JDM, OM

 

95

83.8 (10 yr)

Dankó2004 [15]

Hungary

1976-2002

8.46 years

162

PM, DM, JDM, OM, CAM

95

92

89 (10 yr)

Troyanov2005[7]

France

1967-2001

8.7 years

100

PM. DM, CAM, OM

--

--

73(10 yr)

Airio. 2006 [32]

Finland

1965-1995

11 years

248

(176PM/72DM)

PM, DM

--

75(PM)

63(DM)

55(PM

53(DM)

Torres, et al 2006 [33]

Spain

1976-2005

9 years

107

PM, DM, JM, OM, OM, CAM

92

80

71(10 years)

Yamasaki Y, et al 2011[29]

Japan

1984-2010

---

197

PM, DM, ADM, CADM, OM

85

75

67(10 years)

Ours 2011

China

1986-2010

7.5 years

188

PM, DM, ADM, JM, OM, CAM

93.6%

88.7

81(10 years), 76.6(15 years)

65.6 (20 years)

  1. Ref, reference; PM, polymyositis; DM, dermatomyositis; CAM, cancer associated myositis; OM, overlap myositis; JM, Juvenile PM/DM.